Studying imlifidase in comparison to the standard of | Clinical Research Studies Listing

Recruiting

18 years - 70 years

All

Phase 3

2 participants needed

1 Location

Brief description of study

The purpose of this study is to demonstrate the efficacy and safety of imlifidase in comparison to the standard of care (SoC) in the management of highly sensitized transplant patients.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Kidney Transplant
Age: 18 years - 70 years
Gender: All

Patients with Cronic Kidney Disease stage 5, highly sensitized with a cPRA of 99.9% or higher.

Updated on 04 Aug 2024. Study ID: 850733

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Studying imlifidase in comparison to the standard of care in the management of highly sensitized kidney transplant patients.

Brief description of study

Eligibility of study

Find a site

Interested in the study